References in periodicals archive ?
The findings from this analysis build upon those identified at Week 48 and showed comparable rates of virologic response in patients aged >50 years, females, or in patients who self-reported their race as "black" or "African American" compared to their respective counterparts through Week 96.
The combination of abacavir (ABC) and lamivudine (3TC) is no longer recommended first line; studies have shown reduced virologic efficacy in comparison to TDF/FTC in individuals with an HIV VL >100,000 copies/mL (ACTG A5202) (8), the use of ABC requires HLAB5701 genetic testing before administration, and concerns persist about the cardiac side effects of ABC.
These detected higher rates can be attributed to patients with shorter time to undetectable HBV DNA (<12 weeks), greater HBsAg reduction during therapy (>1 log10), lower end of the HBsAg treatment level (<100 IU/mL), and sustained response (without clinical and/or virologic relapse).
Primary outcomes were viral breakthrough or minor virologic breakthrough after the index date.
According to guideline of prevention and treatment of chronic hepatitis B from APASL [5], virologic relapse was defined as HBV DNA > 2000 IU/mL, while clinical relapse was defined as HBV DNA > 2000 IU/mL and ALT > 2 times upper limit of normal (ULN).
Virologic suppression tended to be better with fixed-dose drugs in randomized trials (RR 1.04, 95% CI 0.99 to 1.10) and observational studies (RR 1.07, 95% CI 0.97 to 1.18).
Virologic failure was defined as a plasma HIV RNA level >400 copies/[micro]l at the last viral load determination.
While individuals with a history of prior psychiatric disorder or active drug use were significantly less likely to achieve sustained virologic response, the integrated-care approach had particularly positive effects on treatment initiative and response for individuals with a risk for active psychiatric disease at baseline, reported Dr.
The overall sustained virologic response at 12 or more weeks after treatment (SVR12) among treated patients was 99%, thus the study met the prespecified primary efficacy endpoint of 85% SVR12, said Dr.
The researchers defined virologic failure in two ways:
Results showed that sustained virologic responses after 12 weeks (SVR12) were 91.8% and 95.9%.
In this study, we assessed virologic, immunologic, and clinical outcomes of ARV-experienced patients who initiated darunavir (DRV)-based salvage therapy in routine care settings.